Genome‐wide analysis of POU3F2/BRN2 promoter occupancy in human melanoma cells reveals Kitl as a novel regulated target gene

POU3F2 is a POU‐Homeodomain transcription factor expressed in neurons and melanoma cells. In melanoma lesions, cells expressing high levels of POU3F2 show enhanced invasive and metastatic capacity that can in part be explained by repression of Micropthalmia‐associated Transcription Factor (MITF) expression via POU3F2 binding to its promoter. To identify other POU3F2 target genes that may be involved in modulating the properties of melanoma cells, we performed ChIP‐chip experiments in 501Mel melanoma cells. 2108 binding loci located in the regulatory regions of 1700 potential target genes were identified. Bioinformatic and experimental assays showed the presence of known POU3F2‐binding motifs, but also many AT‐rich sequences with only partial similarity to the known motifs at the occupied loci. Functional analysis indicates that POU3F2 regulates the stem cell factor (Kit ligand, Kitl) promoter via a cluster of four closely spaced binding sites located in the proximal promoter. Our results suggest that POU3F2 may regulate the properties of melanoma cells via autocrine KIT ligand signalling.

[1]  M. Gottesman,et al.  Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma , 2009, Pigment cell & melanoma research.

[2]  O. Poch,et al.  Cell-Specific Interaction of Retinoic Acid Receptors with Target Genes in Mouse Embryonic Fibroblasts and Embryonic Stem Cells , 2009, Molecular and Cellular Biology.

[3]  E. Sahai,et al.  Intravital imaging reveals transient changes in pigment production and Brn2 expression during metastatic melanoma dissemination. , 2009, Cancer research.

[4]  L. Larue,et al.  Secrets to developing Wnt‐age melanoma revealed , 2009, Pigment cell & melanoma research.

[5]  R. Silverstein,et al.  CD36, a Scavenger Receptor Involved in Immunity, Metabolism, Angiogenesis, and Behavior , 2009, Science Signaling.

[6]  B. Monsarrat,et al.  Expression and purification of human full-length N Oct-3, a transcription factor involved in melanoma growth. , 2009, Protein expression and purification.

[7]  D. Roberts,et al.  Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies , 2009, Nature Reviews Cancer.

[8]  R. Sturm,et al.  POU domain transcription factors: BRN2 as a regulator of melanocytic growth and tumourigenesis , 2008, Pigment cell & melanoma research.

[9]  P. Nuciforo,et al.  Brn-2 represses microphthalmia-associated transcription factor expression and marks a distinct subpopulation of microphthalmia-associated transcription factor-negative melanoma cells. , 2008, Cancer research.

[10]  Helen Pickersgill,et al.  Oncogenic BRAF Regulates Melanoma Proliferation through the Lineage Specific Factor MITF , 2008, PloS one.

[11]  Yimin Zou,et al.  Wnt signaling in neural circuit assembly. , 2008, Annual review of neuroscience.

[12]  E. Dupin,et al.  The stem cells of the neural crest , 2008, Cell cycle.

[13]  Mohamed H. Sayegh,et al.  Identification of cells initiating human melanomas , 2008, Nature.

[14]  R. Losson,et al.  Retinoic acid induces TGFβ-dependent autocrine fibroblast growth , 2008, Oncogene.

[15]  R. Silverstein,et al.  CD36-TSP-HRGP interactions in the regulation of angiogenesis. , 2007, Current pharmaceutical design.

[16]  F. Luciani,et al.  Beta-catenin induces immortalization of melanocytes by suppressing p16INK4a expression and cooperates with N-Ras in melanoma development. , 2007, Genes & development.

[17]  B. Monsarrat,et al.  Differential effects of phosphorylation on DNA binding properties of N Oct-3 are dictated by protein/DNA complex structures. , 2007, Journal of molecular biology.

[18]  L. Nguyen,et al.  Proneural bHLH and Brn proteins coregulate a neurogenic program through cooperative binding to a conserved DNA motif. , 2006, Developmental cell.

[19]  D. Fisher,et al.  c-Met Expression Is Regulated by Mitf in the Melanocyte Lineage* , 2006, Journal of Biological Chemistry.

[20]  L. Perletti,et al.  TAF4 inactivation in embryonic fibroblasts activates TGFβ signalling and autocrine growth , 2005, The EMBO journal.

[21]  Magali Blaud,et al.  Identification of the ‘NORE’ (N-Oct-3 responsive element), a novel structural motif and composite element , 2005, Nucleic acids research.

[22]  T. Natoli,et al.  Hox/Pbx and Brn binding sites mediate Pax3 expression in vitro and in vivo. , 2004, Gene expression patterns : GEP.

[23]  F. Faure,et al.  Involvement of cadherins 7 and 20 in mouse embryogenesis and melanocyte transformation , 2004, Oncogene.

[24]  R. Marais,et al.  The Brn-2 Transcription Factor Links Activated BRAF to Melanoma Proliferation , 2004, Molecular and Cellular Biology.

[25]  L. Larue,et al.  Brn-2 Expression Controls Melanoma Proliferation and Is Directly Regulated by β-Catenin , 2004, Molecular and Cellular Biology.

[26]  L. Martiny,et al.  Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth. , 2004, Critical reviews in oncology/hematology.

[27]  M. Herlyn,et al.  Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. , 2003, The Journal of investigative dermatology.

[28]  B. Wehrle-Haller.  The role of Kit-ligand in melanocyte development and epidermal homeostasis. , 2003, Pigment cell research.

[29]  Tetsuo Noda,et al.  Brn-1 and Brn-2 share crucial roles in the production and positioning of mouse neocortical neurons. , 2002, Genes & development.

[30]  K. Lefort,et al.  The specific activation of gadd45 following UVB radiation requires the POU family gene product N-oct3 in human melanoma cells , 2001, Oncogene.

[31]  M Wilmanns,et al.  Differential dimer activities of the transcription factor Oct-1 by DNA-induced interface swapping. , 2001, Molecular cell.

[32]  Matthias Wilmanns,et al.  Synergism with the Coactivator OBF-1 (OCA-B, BOB-1) Is Mediated by a Specific POU Dimer Configuration , 2000, Cell.

[33]  P. Parsons,et al.  Domains of Brn-2 that mediate homodimerization and interaction with general and melanocytic transcription factors. , 2000, European journal of biochemistry.

[34]  B. Luisi,et al.  The virtuoso of versatility: POU proteins that flex to fit. , 2000, Journal of molecular biology.

[35]  E. Price,et al.  c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. , 2000, Genes & development.

[36]  M. Tainsky,et al.  Loss of AP‐2 results in downregulation of c‐KIT and enhancement of melanoma tumorigenicity and metastasis , 1998, The EMBO journal.

[37]  M. Rosenfeld,et al.  POU domain family values: flexibility, partnerships, and developmental codes. , 1997, Genes & development.

[38]  D. McConkey,et al.  Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. , 1996, Oncogene.

[39]  D. Latchman.  The Oct-2 transcription factor. , 1996, The international journal of biochemistry & cell biology.

[40]  P. Sawchenko,et al.  Development and survival of the endocrine hypothalamus and posterior pituitary gland requires the neuronal POU domain factor Brn-2. , 1995, Genes & development.

[41]  K. Jishage,et al.  The POU domain transcription factor Brn-2 is required for the determination of specific neuronal lineages in the hypothalamus of the mouse. , 1995, Genes & development.

[42]  D. Bennett,et al.  The POU domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression. , 1995, Oncogene.

[43]  G. Sutherland,et al.  The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. , 1995, Oncogene.

[44]  I. Weissman,et al.  Expression of the integrin α4β1 on melanoma cells can inhibit the invasive stage of metastasis formation , 1994, Cell.

[45]  Juli D. Klemm,et al.  Crystal structure of the Oct-1 POU domain bound to an octamer site: DNA recognition with tethered DNA-binding modules , 1994, Cell.

[46]  H. Hamada,et al.  A CNS-specific POU transcription factor, Brn-2, is required for establishing mammalian neural cell lineages , 1993, Neuron.

[47]  J. Manfredi,et al.  Spacing and orientation of bipartite DNA-binding motifs as potential functional determinants for POU domain factors. , 1993, Genes & development.

[48]  R. Perlis,et al.  KIT ligand (mast cell growth factor) inhibits the growth of KIT-expressing melanoma cells. , 1993, Oncogene.

[49]  A. M. van der Bliek,et al.  Multidrug resistance phenotype of human BRO melanoma cells transfected with a wild-type human mdr1 complementary DNA. , 1990, Cancer research.

[50]  P. Chambon,et al.  The HeLa cell protein TEF-1 binds specifically and cooperatively to two SV40 enhancer motifs of unrelated sequence , 1988, Cell.

[51]  M. Vigneron,et al.  In vitro binding of cell‐specific and ubiquitous nuclear proteins to the octamer motif of the SV40 enhancer and related motifs present in other promoters and enhancers. , 1987, The EMBO journal.

[52]  Lin Yang,et al.  Transcriptional regulatory networks in embryonic stem cells. , 2011, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[53]  Ralph Weissleder,et al.  Intravital Imaging , 2011, Cell.

[54]  B. Bastian,et al.  KIT as a therapeutic target in melanoma. , 2010, The Journal of investigative dermatology.

[55]  M. Rosenfeld,et al.  POU domain factors in neural development. , 1998, Advances in experimental medicine and biology.

[56]  C. Pabo,et al.  Oct-1 POU domain-DNA interactions: cooperative binding of isolated subdomains and effects of covalent linkage. , 1996, Genes & development.

[57]  G. Mickisch.  Multidrug Resistance , 1996, Der Urologe A.

[58]  N. Heintz,et al.  Cell-cycle regulation of a human histone H2b gene is mediated by the H2b subtype-specific consensus element. , 1988, Genes & development.

[59]  Ian Chambers,et al.  The transcriptional foundation of pluripotency , 2009, Development.